bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract C90: Working to double pancreatic cancer survival by 2020
Authors: Bason Maurice L. 
Published: May 2016

Abstract
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase survival for people diagnosed with this devastating disease through a bold initiative - The Vision of Progress: Double Pancreatic Cancer Survival by 2020. Together, we can Wage Hope in the fight against pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics and better treatments and increase chances of survival.
Citation Format: Maurice L. Bason. Working to double pancreatic cancer survival by 2020. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr C90.
Abstract C93: LUNA: Latinos United for a New Awakening
Authors: Sifontes Viviam 
Published: May 2016

Abstract
LUNA is a nonprofit organization created by a breast cancer survivor approximately 10 years ago when she found herself navigating the oncology system on her own and in a language that was not her primary one. LUNA stand for Latinos United for a New Awakening and represents what every Latino survivor expresses when given the remission diagnosis after her cancer treatment is completed and is filled with so many uncertainties and hope. LUNA started offering a support/social group where women in particular gather to support each other as they went through their cancer treatments. Soon after, word of mouth brought more women and their relatives with other challenges that LUNA decided to tackle-in as the opportunities presented themselves. With the generous assistance of in-kind sponsorship from organizations such as Moffitt Cancer Center, Cultural Dynamics Specialist, LLS, TBCCN and Morton Plan Hospital, LUNA is recognized as the leading agency of its kind. Two other support groups in two different counties have been added to the list of our programs including as our newest addition. All of our services are free to our clients and offered in Spanish and LUNA is fully run by volunteers. This makes this organization extremely unique. Every year we service approximately 25 women and in the last 6 years we have educated and offered support of some kind to over 400 Latino women.
LUNA's mission is to provide emotional support and health education to cancer survivors from the Latin communities of West Central Florida. LUNA seeks to fill an unmet need in our community, that is provision of support, education, memorable culturally relevant social events, and outreach for cancer Latino cancer survivors/patients, their relatives and friends.
Citation Format: Viviam Sifontes. LUNA: Latinos United for a New Awakening. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr C93.
Abstract C94: Arkansas Cancer Coalition: Mechanisms to advance the implementation of the Arkansas Cancer Plan
Authors: Karanja Miriam 
Published: May 2016

Abstract
ENDING CANCER FOR EVERYONE
The Arkansas Cancer Coalition's mission is to facilitate and provide partnerships to reduce the human suffering and economic burden from cancer for the citizens of Arkansas.
USING EVIDENCE TO IMPROVE OUTCOMES
Making evidence-based practices in prevention, early detection and care available to all Arkansans can dramatically reduce the burden of cancer in our state. Here are just a few examples of programs that address the cancer continuum in Arkansas:
Annual Arkansas Cancer Summit
Arkansas Cancer Plan Grants
Coalition Engagement
Quarterly Meetings
Trainings
To address this major public health problem, the Arkansas Cancer Coalition developed the Arkansas Cancer Plan--A Framework for Action (ACP). This ambitious plan updated in 2007 and endorsed by a wide range of stakeholders and partners, established 26 broad goals in the strategic areas of: prevention, screening and detection, treatment, disparities, research, workforce development, survivorship, palliative care, professional education, surveillance, and evaluation.
The poster describes the implementation of the ACP through two main mechanisms in terms of their foci and partnerships, and shares lessons learned as they engaged underserved communities. First, grantees were invited to participate in implementation efforts that are perceived to take more than one year to implement. Second, competitive grantees were established to achieve short-term objectives of the ACP.
Citation Format: Miriam Karanja. Arkansas Cancer Coalition: Mechanisms to advance the implementation of the Arkansas Cancer Plan. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr C94.
Abstract C95: Cancer health disparities in the U.S
Authors: Francoeur Jeri 
Published: May 2016

Abstract
Florida Breast Cancer Foundation and Susan G. Komen have similar missions in that they both are dedicated to ending breast cancer through advocacy, education and research and empowering others and ensuring quality care for all. Komen is at a global level whole Florida Breast Cancer Foundation is the State's breast cancer organization as it received the majority of its funds through the state license plate. This poster shows cancer disparities in the US, what they are, needs, and possible solutions. It will indicate the areas where more work is needed and hopefully will encourage others to become more involved through advocacy.
Citation Format: Jeri Francoeur. Cancer health disparities in the U.S. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr C95.
Abstract C97: Destination Hope: Survivor support to enhance quality of life
Authors: Glosik Elizabeth (Betsy) 
Published: May 2016

Abstract
Destination Hope is a non-profit organization which provides uplifting and positive retreat support services for individuals in cancer treatment and their families. Each retreat is designed to be unique to the event space and address the specific needs of the participant group. Programs incorporate and teach healing and holistic approaches for self-care. Services are provided free of charge or with a minimal registration fee that may be waved for those who cannot afford it. This poster describes: retreat types, description of elements included in retreats, collaborative relationships with other non-profit providers, analysis of benefits obtained by participants, funding, participant recruitment, participant comments, and supporting evidence from research regarding the benefits of complementary and holistic therapies. Photographs of events are also included.
Citation Format: Elizabeth (Betsy) Glosik. Destination Hope: Survivor support to enhance quality of life. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr C97.
Abstract IA10: Financial distress in patients with cancer: Contributing factors and potential solutions
Authors: Shankaran Veena 
Published: May 2016

Abstract
As the cost of cancer care in the United States continues to rise at an unprecedented rate, cancer patients are struggling to pay their share of the bill. Along with other measures of financial distress, cancer patients are 2.65 times more likely to file for bankruptcy than patients without cancer. Several recent reports suggest that individuals who face such financial challenges during treatment are more likely to report treatment non-adherence, poorer quality of life, and may suffer worse clinical outcomes. Despite an increasing awareness of “financial toxicity” among cancer patients, few oncology practices have processes in place to identify high out-of-pocket spending for cancer care and to provide assistance to patients struggling to pay for treatment or manage other life expenses. Given the rising cost of cancer care and its growing impact on cancer patients' financial health, the oncology community must be proactive in developing tools to steer vulnerable patients towards appropriate resources to reduce or prevent financial crisis. Such an approach may help to reduce disparities in treatment, adherence, and outcomes faced by cancer patients with limited financial reserves.
Addressing the patient-level financial burden of cancer care requires a multifaceted approach, including efforts at the policy level to negotiate pharmaceutical drug prices and improve structure of existing health insurance plans (e.g. Patient Protection and Affordable Care Act). At the health system and payer level, efforts to improve cost transparency may decrease waste and price variation while improving care quality.
At the patient and provider level, we propose several solutions that may also help to mitigate the financial burden of cancer treatment: 1) develop tools to track patient out-of-pocket costs and level of financial distress in real time; 2) develop strategies to align patients with available financial assistance resources from the time of diagnosis; 3) improve transparency about available effective treatment options and associated out-of-pocket costs to improve shared decision-making. In the era of widespread mobile phone and smartphone use across all racial and income groups, leveraging mobile technology to accomplish some of these goals is particularly appealing.
Citation Format: Veena Shankaran. Financial distress in patients with cancer: Contributing factors and potential solutions. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr IA10.
Abstract IA27: NCORP cancer care delivery research: A new opportunity for studying cancer disparities
Authors: Geiger Ann M. 
Published: May 2016

Abstract
Limitations in the availability and quality of cancer care have been associated with poor outcomes in medically underserved populations, independent of any biological factors. Differential access and care variation have been documented for many types of cancer and in all phases of care from screening through end-of-life. Patient-level interventions have had a modest impact on cancer disparities that arise in the process of care delivery. Challenges to further understanding and addressing care disparities include reliance on secondary use of data collected for other purposes (e.g., SEER-Medicare) and primary data collection in settings not reflective of the community (e.g., integrated delivery systems).
The NCI Community Oncology Research Program (NCORP) integrates a cancer care delivery component offering a new opportunity to study cancer disparities. Cancer care delivery research is defined as the development of “new and generalizable knowledge about the effectiveness, acceptability, cost, optimal delivery mode, active ingredients, and causal mechanisms that influence outcomes and affect the value of cancer care, across diverse settings and populations” (Kent EE et al. J Clin Oncol 2015; 33:2705-11). The ultimate goal is “evidence-based practice change [that will] improve clinical outcomes, enhance patient experiences, and optimize value” (Kent et al.). As is the case for all NCORP efforts, cancer care delivery research considers issues of the medically underserved, particularly racial/ethnic minorities and rural residents, a particular focus.
This presentation will describe cancer care delivery research and provide examples of cancer care disparities research that could be conducted within NCORP.
Citation Format: Ann M. Geiger. NCORP cancer care delivery research: A new opportunity for studying cancer disparities. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr IA27.
Abstract IA30: Approaching “precision disparities” in cervical cancer outcomes
Authors: Kobetz Erin , Rao R. Sunil , Yu Huilin , Miller Phillip , Garcia Ruslan , Hew Karina , Seay Julia 
Published: May 2016

Abstract
In the United States, Black women experience an increased risk of developing and dying from cervical cancer, primarily due to more advanced stage of disease at diagnosis. Black women tend to be diagnosed with later stage disease, when the prognosis for survival is poor, despite screening rates that meet and in some instances, exceed, those reported for white women. Thus, the observed survival difference between women of varying race/ethnicity may, in part, be biologically based. Research has identified key differences in the genotype, or strain, of Human Papillomavirus (HPV) associated with the cervical tumors of Black vs. white women with disease, and also found racial variability in the mutations expressed in other cancer sites. However, little is known about racial variability in epigenetic processes associated with disease onset and progression in cervical cancer, though there is increasing evidence that the methylation status of genes involved in carcinogenesis also varies by race. This is perhaps not surprising. Epigenetic alterations, such as DNA methylation, play an important role in various cellular functions, and are influenced by known cancer risk factors, including diet, tobacco, alcohol consumption, stress, and socio-environmental conditions, among others. Such factors vary across the population at large and between racial/ethnic groups, specifically. Blacks also have higher levels of methylation at birth relative to their white counterparts and, therefore, may be exposed to poorer outcomes, given the likely interaction between baseline biology and undue exposure to causal risk factors and risk conditions. We have developed a novel statistical approach, PRISM, which enables a more intuitive understanding of how biological factors interact with more upstream, social determinants to influence disease etiology and outcome. Using PRISM, we examine data from the publically available Cancer Genome Atlas (TCGA), and our ongoing work in Little Haiti, the largest enclave of Haitian settlement in the United States, to better understand the complex interplay between multilevel determinants of cervical cancer on disease survival.
Citation Format: Erin Kobetz, R. Sunil Rao, Huilin Yu, Phillip Miller, Ruslan Garcia, Karina Hew, Julia Seay. Approaching “precision disparities” in cervical cancer outcomes. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr IA30.
Abstract IA34: Evaluating methods of improving quality of life for cancer patients and improving acceptance of screening practices among cancer patients and their families
Authors: Manne Sharon L. 
Published: May 2016

Abstract
Dr. Manne will describe her ongoing R01 trial evaluating an intimacy-enhancing couples counseling versus a diet and exercise intervention and minimal care. She will also discuss the state of the science in quality of life for men with prostate cancer and their intimate relationships as well as important areas for future research.
Citation Format: Sharon L. Manne. Evaluating methods of improving quality of life for cancer patients and improving acceptance of screening practices among cancer patients and their families. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr IA34.
Abstract IA38: NCI MATCH: A national precision medicine trial – Conception, development, and adjustment
Authors: Conley Barbara A. 
Published: May 2016

Abstract
Precision medicine trials aim to provide evidence that targeting particular molecular abnormalities with specific treatment will result in better efficacy than current methods. While we know certain instances where the tumor type influences response to these agents, there are other instances where responses can be seen in various malignancies if they have the same molecular abnormality. Currently we do not know much about why some tumors or even most tumors will respond to a treatment, given the same mutation, and some do not. NCI MATCH is a national signal-finding trial for patients with solid tumors or lymphomas that have progressed after standard treatment. Patients register to a screening trial, have a biopsy of their tumor, and the tumor is analyzed by a targeted next generation sequencing panel and appropriate other molecular assays, and if an actionable mutation (one that can be addressed in MATCH) is found, the patient is evaluated for treatment with the appropriately matched drug(s). The goal is to seek a signal that targeting a molecular abnormality across tumors can be successful. The trial is open in hundreds of academic and community oncology sites through the National Clinical Trials Network of the NCI. The trial uses rules by which to assign a treatment, and depends on previous evidence that a given molecular abnormality is involved in cancer maintenance, and/or could result in a response to a given treatment. As most molecular abnormalities will occur in 10% or less of patients, the trial requires a large screening population and a large number of treatments within it. The trial is meant to change to accommodate new knowledge, and to expand as necessary to follow signals. We have an opportunity to study additional problems within NCI MATCH as well, such as molecular features of responders vs. non-responders, evaluation of genomic knowledge of patients, potential inheritable abnormalities that are also seen in the tumor, as well as study recruitment and retention issues within the trial. The talk will discuss the rules created for the trial, the initial early challenges, and some new areas of exploration going forward.
Citation Format: Barbara A. Conley. NCI MATCH: A national precision medicine trial – Conception, development, and adjustment. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr IA38.
Abstract A02: Stat3 plays a critical role in the establishment of immunosuppressive tumor microenvironment: Implications for tumor immunsurviellance and metastatic progression
Authors: Jones Laura M. , Broz Miranda , Ranger Jill , Ursini-Siegel Josie , Krummel Matthew , Muller William J. 
Published: May 2016

Abstract
Immune surveillance is thought to play a critical role in promoting the elimination of developing malignant lesions through activation of immune response. However, cancer cells eventually acquire the ability to escape immune surveillance by favoring recruitment of immune cell types that exert an inflammatory and immunosuppressive state. Despite the importance of immune surveillance, the molecular mechanisms that promote escape from immune remains poorly defined. Here we demonstrate that expression of the Stat3 transcription factor in the tumor epithelial is involved in promoting an immunosuppressive tumor microenvironment. To investigate the role of Stat3 in modulating the tumor immune-microenvironment, we ablated Stat3 in the tumor epithelia of an inducible PyV mT model of mammary tumor progression. Molecular and pathological analyses of tumor progression revealed that Stat3 deficient tumors were initially able to form hyperplastic and early adenoma–like lesions with no obvious impact on the proliferative or apoptotic status on these epithelial lesions. However, these early premalignant lesions completely regressed, thereby preventing the emergence of mammary tumors in the majority of animals. Tumor regression was correlated with a massive infiltration of T lymphocytes and F4/80 positive macrophages into Stat3 deficient lesions. However focal Stat3 deficient mammary tumors escaped immune surveillance after a long latency period in a minority of the affected animals. Our data argue that tumor epithelial expression of Stat3 plays a critical role in promoting an immune suppressive tumor microenvironment .
Note: This abstract was not presented at the conference.
Citation Format: Laura M. Jones, Miranda Broz, Jill Ranger, Josie Ursini-Siegel, Matthew Krummel, William J. Muller. Stat3 plays a critical role in the establishment of immunosuppressive tumor microenvironment: Implications for tumor immunsurviellance and metastatic progression. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Breast Cancer Research; Oct 17-20, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(2_Suppl):Abstract nr A02.